Residents of Moscow technology parks have created two new medical innovations (a membrane to restore cartilage tissue in joints and a high-tech blood analyzer) that help to early diagnose illnesses and treat patients effectively, Moscow Mayor’s web page reports.
A resident of the Mosgormash Technology Park, for instance, designed membranes to regenerate cartilage tissue in joints. They speed up cell regeneration. A surgeon is to implant a plate, fixing it on a damaged joint with special glue or suture material. It is a bio-resorbable (or biocompatible) membrane: as it dissolves, it is replaced by body tissue. Bioresorption takes about two months, and the plate does not release toxic substances into a patient’s body. The innovation can be used to treat typical joint damage from head and leg injuries. The membrane does not only help speed up recovery but also helps avoid joint replacement.
The innovation is the first of its kind in Russia. Similar membranes were produced in Germany and Switzerland. The Russian membrane’s advantage is that it is synthesized from collagen nanofibers while other products are made from materials of animal origin. The Russian membranes are more flexible and efficient. In addition, the plates are double-sided, so they are easier to use in surgery. If required, doctors can order customized products.
A resident of the Strogino Technology Park has come up with Lazma PF, a high-tech mobile blood analyzer. Unlike its Japanese equivalent, the device is smaller (size of a watch) and easier to us. The analyzer can measure venous and arterial blood as well as capillary blood (which is responsible for nourishing body and skin cells). The analyzer determines the state of microcirculation and body blood temperature. It can help diagnose early stages of vascular diseases that can result in complications if not properly treated (such as ulcers). The device will also be useful in diagnosing problems with joint mechanics: for example, if a joint constricts blood vessels and thus interferes with blood microcirculation. The device will record whether changes in blood flow occur in the morning, afternoon or evening.
The mobile blood analyzer can be used in hospitals and clinics as well as for self-diagnostics at home. The device’s laser analyses the body markers and shows the results on the screen of a PC or any device connected to it via Bluetooth or Wi-Fi. It is safe and easy to use. Lazma PF will soon enter the Russian market. The inventor is also patenting it in Europe, the US, CIS, South Korea, China and India.
Innovative medical tools and machines are designed in the Elma and Slava technology parks as well. An Elma resident specializes in diagnostics and therapeutic equipment, such as electrocardiographs (ECG), electroencephalographs (EEG), automatic defibrillators and resuscitation massagers. In the Slava Technology Park, residents design reagent kits for molecular genetic research. They also produce coronavirus PCR testing systems.
As of today, there are 36 technology parks in Moscow, with over 2K residents and other tenants (13 of them are anchor residents). Moreover, four priority investment projects to establish new technology parks are underway. Resident status allows holders to use various support measures from the Moscow Government, so that companies can lower their tax burden by 25%. Anchor residents can get a regional income tax cut of up to 12.5%. The park’s managing companies can also obtain subsidies to partially cover their interest on loans for creating or developing the property.
In 15 of Moscow technology parks there are 73 resident companies that specialize in medical and pharmaceutical R&D. Their solutions are important for healthcare and widely used in leading Russian clinics and hospitals. Many of their products have no analogues in Russia.